刺五加改善原发性睡眠障碍患者的睡眠质量:随机对照观察

Randomized controlled observation on the effect of acanthopanax injection in improving primary sleep disorder

目的:观察刺五加注射液治疗原发性睡眠障碍的疗效。方法:将60例原发性睡眠障碍的患者抽签随机分成刺五加治疗组及对照组。治疗组静脉滴注刺五加注射液60mL加生理盐水250mL,1次/d,14d为1个疗程。对照组不应用刺五加,静脉滴注加生理盐水250mL,1次/d,14d为1个疗程。其余药物与治疗组相同。其后采用匹兹堡睡眠质量指数量表进行睡眠质量评定比较。结果:治疗组总有效率为87%(26/30),对照组为47%(14/30),两组疗效比较,差别有统计学意义(χ2=3.54,P<0.01);两组的匹茨堡睡眠质量指数量表评分比较显示,治疗组治疗后总分为(4.39±3.15)分,低于对照组(9.10±3.96)分,两者比较差异有显著性意义(t=2.13,P<0.05),在其他分项上治疗组疗效均优于对照组(t=2.02～3.18,P<0.05)。结论:刺五加注射液能有效治疗原发性睡眠障碍,其机制可能与它能调节机体的神经内分泌活动有关。

AIM:To study the effect of acanthopanax injection in improvement of primary sleep disorder.METHODS:Sixty patients with primary sleep disorder were randomly divided into acanthopanax injection group(treatment group) and control group of 30 cases each.The patients in the treatment group were administered intravenously with 60 mL acanthopanax injection and 250 mL saline,once daily successively for 14 days as a course.The patients in the control group were injected with the same project as the treatment group except for acanthopanax injection once a day for 14 days as a course.Pittsburgh sleep quality index(PSQI) was used to evaluate the sleep quality.RESULTS:The total effective rates were 87%(26/30) for the treatment group and 47%(14/30) for the control group,and there was a significant difference between the two groups (χ2=3.54,P< 0.01).In the PSQI evaluation,the total scores after treatment were 4.39±3.15 and 9.10±3.96 for the two groups respectively,with significant difference(t=2.13,P< 0.05);While the curative effects of other items were better in the treatment group than in the control group(t=2.02-3.48,P< 0.05).CONCLUSION:Acanthopanax injection can effectively improve primary sleep disorder,and its mechanism may be related with its role in regulation of neruoendocrine function.